Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Association between CHADS2 score, depressive symptoms, and quality of life in a general population

  • Guo-Zhe Sun1,
  • Ning Ye1,
  • Nai-Jin Zhang1,
  • Yuan Li1,
  • Shuang Chen1,
  • Ye Chang1,
  • Zhao Li1 and
  • Ying-Xian Sun1Email author
BMC PsychiatryBMC series – open, inclusive and trusted201717:80

DOI: 10.1186/s12888-017-1214-5

Received: 9 July 2016

Accepted: 24 January 2017

Published: 27 February 2017

Abstract

Background

To investigate the association between CHADS2 score, depressive symptoms, and quality of life in a large general population from China.

Methods

A cross-sectional study of 11,956 permanent residents of Liaoning Province in China ≥ 35 years of age was conducted between January and August 2013 (response rate 85.3%). All participants completed a questionnaire, had a physical examination, and underwent blood examination. Depressive symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9), while the quality of life (QoL) was measured using the World Health Organization Quality of Life Brief Scale (WHOQOL-BREF).

Results

With increasing CHADS2 score, the prevalence of depressive symptoms increased from 4.9 to 27.8% (P < 0.001), and all scores of WHOQOL-BREF decreased significantly (all Ps < 0.001). After adjusting for confounding risk factors, subjects with CHADS2 score ≥ 3 had higher risk of depressive symptoms than those with CHADS2 score = 0 (all Ps < 0.05). Also, CHADS2 score was negatively associated with all scores of WHOQOL-BREF (all Ps < 0.001). Furthermore, subjects with any item in CHADS2 had higher prevalence of depressive symptoms (all Ps < 0.001). Heart failure and stroke remained independently associated with depressive symptoms after adjusting for confounding risk factors and other items (Ps < 0.001), while heart failure, age ≥ 75 years, diabetes mellitus, and stroke were all independently negatively associated with the total score of WHOQOL-BREF (all Ps < 0.05).

Conclusions

The CHADS2 score is significantly associated with depressive symptoms and impaired quality of life in the general population.

Keywords

CHADS2 score Patient Health Questionnaire-9 World Health Organization Quality of Life Brief Scale Depressive symptoms Quality of life

Background

Depression is a worldwide public health problem [1, 2], and depressive disorder has become one of the leading causes of worldwide disability [3], which could contribute to an increased risk of all-cause mortality [4]. High prevalence of depression has been reported in patients with cardiovascular diseases (CVD) and its presence increases the risk for adverse cardiovascular events [5]. However, the awareness of depressive symptoms among such population is quite low and the majority of them are not appropriately treated and controlled. Therefore, identifying all the epidemiological characteristics for depressive symptoms will help to create population-based strategies to prevent and treat this serious health problem.

In recent years, the measurement of health has been broadened beyond traditional health indicators such as mortality and morbidity. Thus, quality of life (QoL) is defined by the World Health Organization (WHO) as individuals’ perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns [6]. It has received growing attention recently, and can be impaired in patients with established CVD [7] or in individuals at high risk of CVD [8].

The CHADS2 score is a simple but reliable clinical scheme, which includes congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and prior stroke or transient ischemic attack. It has been widely used to assess the risk of stroke for patients with atrial fibrillation (AF) [9, 10]. Moreover, the application of the CHADS2 score was not limited in AF population or assessing the risk of stroke in recent studies. In patients with acute coronary syndrome with or without AF, the score could be used as a risk assessment tool for mortality [11]. Furthermore, the score is newly found to be associated with peripheral arterial occlusive disease in patients without AF [12].

However, the association of the CHADS2 score with depressive symptoms and QoL has never been reported, even though the prevalence of depression has been proved to be apparently higher in heart failure [13], hypertension [14], diabetes [15], and stroke [16] than in the general population [17]. Therefore, the current study was designed to explore the association between the CHADS2 score, depressive symptoms, and QoL in a general Chinese population.

Methods

Study population

A representative sample of men and women ≥ 35 years of age from Liaoning Province was recruited between January 2013 and August 2013, using a multi-stage, randomly stratified, cluster-sampling scheme, which is called the Northeast China Rural Cardiovascular Health Study (NCRCHS). And our current study about CHADS2 score, depressive symptoms, and quality of life was part of the NCRCHS. Three counties (Dawa, Zhangwu, and Liaoyang) were selected from the eastern, southern, and northern regions of Liaoning Province. One township near a city in each county was randomly selected giving a total of three townships. Six to eight villages from each township were randomly selected to give a total of 26 rural villages. All of the eligible permanent residents aged ≥ 35 years from each village (n = 14,016) were invited to participate in the study, and 11,956 (response rate 85.3%) agreed to do so. Participants with pregnancy and malignant tumor were excluded from the present study. And subjects with severe mental disorders (for example psychosis) who couldn’t complete the face-to-face survey of NCRCHS were also excluded.

The study was approved by the Ethics Committee of China Medical University (Shenyang, China). All procedures were performed in accordance with the ethical standards. Written consent was obtained from all participants after they had been informed of the study’s objectives, benefits, medical procedures, and confidentiality safeguards for personal information. In the case of an illiterate participant, written informed consent was obtained from the appropriate legal proxy.

Data collection and measurement

Data were collected during a single clinic visit by doctors and trained nurses using a standard questionnaire in a face-to-face interview. All potential investigators had received training on the objectives of the study, how to administer the questionnaire, the standard methods of measurement, the importance of standardization, and study procedures. Only those who earned a perfect score on a post-training test were allowed to participate as study investigators. During data collection, the inspectors received further instructions and support.

Data on the demographic characteristics, lifestyle risk factors, family income, medical history of hypertension, congestive heart failure, stroke, diabetes mellitus, depressive symptoms, and quality of life were obtained, as described above, by interview with the standardized questionnaire. There was a central steering committee with a subcommittee for quality control that made sure all data were collected according to well-known standards.

Depressive symptoms

Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), which was a 9-item screening instrument and widely used in primary health centers with high reliability and validity [18, 19]. Participants were asked how often, over the past 2 weeks, they had been bothered by each of the depressive symptoms with the score ranging from 0 to 3. Then, the total score of PHQ-9 ranged from 0 to 27. The severity of depressive disorder was considered mild for score of 5 to 9, moderate for score of 10 to 14, moderately severe for score of 15 to 19 and severe for score of 20 to 27. A PHQ-9 score ≥ 10 was recommended as the cut-off score for detecting major depressive disorders [20].

Quality of life

The quality of life was measured with the World Health Organization Quality of Life Brief Scale (WHOQOL-BREF), which was a self-report inventory with 26 original items [21, 22]. The items fell into four domains: the physical health (7 items), the psychological health (6 items), the social relationships (3 items), and the environment (8 items), together with 2 items measuring the overall QoL and general health. Each item was answered on a 5-point response scale, and the range of score for each domain was from 4 to 20 after calculation, with higher score indicating better QoL.

CHADS2 score

The CHADS2 score was calculated for each subject based on the point system with 2 points for a history of stroke and 1 point for congestive heart failure, hypertension, an age ≥ 75 years and diabetes mellitus. Congestive heart failure was assigned positive if they had ever been told by a physician that they had congestive heart failure [23]. Similarly, stroke was defined as a history of prior stroke or transient ischemic attack. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg and/or the use of antihypertensive medications according to the Eighth Joint National Committee on the guidelines for the management of high blood pressure in adults (JNC-8) [24]. World Health Organization criteria were followed for defining diabetes mellitus (fasting blood glucose ≥ 7.0 mmol/L or 126 mg/dL, and/or being on treatment for diabetes) [25].

Covariate measurements

Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with the participants in lightweight clothing without shoes. The body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters.

Fasting blood samples were collected in the morning after ≥ 8 h of fasting for all participants. Blood samples were obtained from an antecubital vein using BD Vacutainer tubes containing EDTA. Serum was subsequently isolated from whole blood, and all serum samples were frozen at −20 °C for testing at a central, certified laboratory. Fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high density lipid cholesterol (HDL-C), low density lipid cholesterol (LDL-C), serum uric acid, serum creatinine, and other routine blood indices were analyzed enzymatically on an auto-Analyzer. Glomerular filtration rate (GFR) was estimated using the equation originating from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [26].

Physical activity included occupational and leisure-time physical activity, and a detailed description of these standards has been presented [27]. The combination of occupational and leisure-time physical activity was therefore described as low (light levels of activity in both categories), moderate (moderate or high levels of activity in one of the categories), or high (moderate or high levels of activity in both categories).

Statistical analysis

All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences between groups were compared using two-tailed Student’s t-test, ANOVA or the χ 2 test as appropriate. The prevalences of depressive symptoms among different CHADS2 score were calculated, and the total score of WHOQOL-BREF by PHQ-9 score and CHADS2 score was also presented. Both univariate and multivariate logistic regression analyses were performed to estimate the crude and independent associations between each item in CHADS2, CHADS2 score, and depressive symptoms. Multivariate linear regression analysis and optimal scale regression analysis were conducted to assess the independent associations of each item in CHADS2 and CHADS2 score with WHOQOL-BREF score, respectively. P < 0.05 was considered as statistically significant.

Results

Characteristics of the study population

Of the 11,956 participants, 896 had incomplete data and were excluded from the analysis, leaving a total of 11,060 participants (5080 men and 5980 women) with a mean age of 53.9 years. The subjects with moderate or severe depressive symptoms were significantly older and had lower percentage of men than those with no or mild depressive symptoms (Ps < 0.001) (Table 1). The subjects with moderate or severe depressive symptoms had significantly higher FBG, TG (all Ps < 0.05), and lower eGFR levels (P < 0.001). They also had a lower percentage of alcohol drinking and smoking and lower levels of education, income, physical activity and sleep time (all Ps < 0.001). In addition, the subjects with moderate or severe depressive symptoms had significantly higher levels of CHADS2 score and lower scores of WHOQOL-BREF (all Ps < 0.001). However, there were no significant differences in BMI, SBP, DBP, TC, HDL-C, LDL-C, or serum uric acid between the two groups.
Table 1

Comparison of the characteristics of the study sample

Variable

All (n = 11,060)

Depressive symptoms

P value

No or mild (n = 10,390)

Moderate or severe (n = 670)

Age, years

53.9 ± 10.5

53.7 ± 10.5

57.1 ± 10.2

<0.001

Male

5080 (45.9)

4898 (47.1)

182 (27.2)

<0.001

BMI, kg/m2

24.8 ± 3.7

24.8 ± 3.7

24.5 ± 3.8

0.050

SBP, mmHg

141.6 ± 23.3

141.5 ± 23.2

143.5 ± 25.5

0.051

DBP, mmHg

82.0 ± 11.7

82.0 ± 11.7

82.2 ± 11.8

0.603

FBG, mmol/L

5.91 ± 1.62

5.90 ± 1.61

6.09 ± 1.76

0.006

TC, mmol/L

5.24 ± 1.09

5.23 ± 1.08

5.31 ± 1.18

0.124

TG, mmol/L

1.63 ± 1.47

1.62 ± 1.47

1.75 ± 1.51

0.030

HDL-C, mmol/L

1.41 ± 0.38

1.41 ± 0.38

1.40 ± 0.40

0.601

LDL-C, mmol/L

2.93 ± 0.82

2.92 ± 0.82

2.96 ± 0.89

0.290

Serum uric acid, umol/L

292 ± 85

292 ± 85

289 ± 90

0.344

eGFR, ml/min/1.73 m2

92.8 ± 15.9

93.1 ± 15.7

88.6 ± 18.3

<0.001

Current smoker

3886 (35.1)

3693 (35.5)

193 (28.8)

<0.001

Current drinker

2474 (22.4)

2402 (23.1)

72 (10.7)

<0.001

Education level

   

<0.001

  ≤ Primary school

5539 (50.1)

5095 (49.0)

444 (66.3)

 

 Middle school

4491 (40.6)

4296 (41.3)

195 (29.1)

 

  ≥ High school

1030 (9.3)

999 (9.6)

31 (4.6)

 

Family income, CNY/year

   

<0.001

  ≤ 5000

1379 (12.5)

1209 (11.6)

170 (25.4)

 

 5000–20,000

6025 (54.5)

5655 (54.4)

370 (55.2)

 

  > 20,000

3656 (33.1)

3526 (33.9)

130 (19.4)

 

Physical activity

   

<0.001

 Low

3263 (29.5)

2953 (28.4)

310 (46.3)

 

 Moderate

7164 (64.8)

6830 (65.7)

334 (49.9)

 

 High

633 (5.7)

607 (5.8)

26 (3.9)

 

Sleep duration, h/day

7.3 ± 1.7

7.3 ± 1.6

6.2 ± 2.1

<0.001

Congestive heart failure

102 (0.9)

78 (0.8)

24 (3.6)

<0.001

Hypertension

5623 (50.8)

5234 (50.4)

389 (58.1)

<0.001

Age ≥ 75 years

332 (3.0)

297 (2.9)

35 (5.2)

0.001

Diabetes mellitus

1154 (10.4)

1051 (10.1)

103 (15.4)

<0.001

Stroke

976 (8.8)

848 (8.2)

128 (19.1)

<0.001

CHADS2 score

0.83 ± 0.96

0.80 ± 0.94

1.20 ± 1.25

<0.001

WHOQOL-BREF domain

    

 Physical health

15.1 ± 2.3

15.4 ± 2.1

11.5 ± 2.5

<0.001

 Psychological

14.5 ± 2.4

14.8 ± 2.2

10.7 ± 2.6

<0.001

 Social relationships

14.6 ± 2.1

14.7 ± 2.0

13.0 ± 2.4

<0.001

 Environment

13.5 ± 2.1

13.6 ± 2.1

11.7 ± 2.1

<0.001

Data are expressed as mean ± standard deviation or n (%)

Abbreviations: BMI body mass index, CNY China Yuan, DBP diastolic blood pressure, FBG fasting blood glucose, eGFR estimated glomerular filtration rate, HDL-C high density lipid cholesterol, LDL-C low density lipid cholesterol, SBP systolic blood pressure, TC total cholesterol, TG triglycerides, WHOQOL-BREF the World Health Organization Quality of Life Brief Scale

Prevalence of depressive symptoms and QoL by CHADS2 score

The prevalence of depressive symptoms (PHQ-9 score ≥ 10) by CHADS2 score was summarized (Fig. 1 and Table 2). It was found that the percentage of subjects with depressive symptoms increased significantly with increasing CHADS2 score, from the lowest of 4.9% to the highest of 27.8% (P < 0.001). The QoL evaluated by WHOQOL-BREF was described according to CHADS2 score (Table 3). As a result, the mean scores for total and every domain of WHOQOL-BREF decreased significantly with increasing CHADS2 score (all Ps < 0.001). The association of CHADS2 score with the total score of WHOQOL-BREF stratified by depressive symptoms was also examined and presented (Fig. 2). The total score of WHOQOL-BREF decreased siginificantly with increasing CHADS2 score in both subgroups (Ps < 0.001). The lowest level of total score was found in subjects with CHADS2 score of 0, while the highest was in those with CHADS2 score of 5.
Fig. 1

Prevalence of depressive symptoms by CHADS 2 score. Percentage of subjects with a PHQ-9 score ≥ 10 increases with increasing CHADS2 score (P < 0.001). Error bars represent standard deviation. PHQ-9: Patient Health Questionnaire-9

Table 2

Logistic regression analyses for associations between CHADS2 score and depressive symptoms (PHQ-9 score ≥ 10)

 

Total (n)

Depressive symptoms n (%)

Unadjusted model

Adjusted model 1

Adjusted model 2

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

Congestive heart failure

        

 No

10,958

646 (5.9)

1

 

1

 

1

 

 Yes

102

24 (23.5)

4.91 (3.09–7.81)

<0.001

3.17 (1.91–5.25)

<0.001

2.98 (1.79–4.96)

<0.001

Hypertension

        

 No

5437

281 (5.2)

1

 

1

 

1

 

 Yes

5623

389 (6.9)

1.36 (1.16–1.60)

<0.001

1.15 (0.96–1.37)

0.127

1.04 (0.87–1.24)

0.687

Age ≥ 75 years

        

 No

10,728

635 (5.9)

1

 

1

 

1

 

 Yes

332

35 (10.5)

1.87 (1.31–2.68)

0.001

1.01 (0.68–1.51)

0.957

1.04 (0.70–1.55)

0.851

Diabetes mellitus

        

 No

9906

567 (5.7)

1

 

1

 

1

 

 Yes

1154

103 (8.9)

1.61 (1.30–2.01)

<0.001

1.35 (1.07–1.72)

0.013

1.25 (0.98–1.59)

0.076

Stroke

        

 No

10,084

542 (5.4)

1

 

1

 

1

 

 Yes

976

128 (13.1)

2.66 (2.17–3.26)

<0.001

2.02 (1.62–2.53)

<0.001

1.96 (1.56–2.46)

<0.001

CHADS2 score

        

 0

4888

238 (4.9)

1

 

1

   

 1

4253

229 (5.4)

1.11 (0.92–1.34)

0.265

1.02 (0.83–1.24)

0.872

  

 2

1093

82 (7.5)

1.59 (1.22–2.06)

0.001

1.15 (0.87–1.53)

0.329

  

 3

598

75 (12.5)

2.80 (2.13–3.69)

<0.001

1.99 (1.47–2.68)

<0.001

  

 4

210

41 (19.5)

4.74 (3.29–6.83)

<0.001

3.47 (2.29–5.25)

<0.001

  

 5

18

5 (27.8)

7.52 (2.66–21.25)

<0.001

3.94 (1.28–12.12)

0.017

  

Adjusted model 1: adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid cholesterol, serum uric acid, estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, and sleep time; Adjusted model 2: adjusted for factors in model 1 and other items in CHADS2

Abbreviations: CI confidence interval, OR odds ratio, PHQ-9 Patient Health Questionnaire-9

Table 3

The mean score of WHOQOL-BREF based on CHADS2 score

 

CHADS2 score

P value

0 (n = 4888)

1 (n = 4253)

2 (n = 1093)

3 (n = 598)

4 (n = 210)

5 (n = 18)

Overall Quality of life

3.30 ± 0.70

3.28 ± 0.68

3.23 ± 0.73

3.15 ± 0.63

3.02 ± 0.72

2.94 ± 0.64

<0.001

General health

3.49 ± 0.82

3.39 ± 0.83

3.24 ± 0.91

2.95 ± 0.89

2.64 ± 0.85

2.72 ± 1.02

<0.001

Domains

       

 Physical health

15.5 ± 2.1

15.2 ± 2.2

14.5 ± 2.5

13.7 ± 2.5

12.5 ± 2.9

11.6 ± 3.1

<0.001

 Psychological

14.7 ± 2.4

14.7 ± 2.4

14.2 ± 2.5

13.6 ± 2.5

12.9 ± 3.0

12.2 ± 3.0

<0.001

 Social relationships

14.9 ± 2.1

14.7 ± 2.0

14.2 ± 2.2

13.9 ± 2.1

13.2 ± 2.4

12.6 ± 2.1

<0.001

 Environment

13.6 ± 2.1

13.5 ± 2.1

13.3 ± 2.2

13.0 ± 2.1

12.7 ± 2.3

12.5 ± 1.9

<0.001

Total Score

65.4 ± 8.2

64.8 ± 8.0

62.7 ± 8.9

60.2 ± 8.4

57.0 ± 9.8

54.6 ± 9.2

<0.001

Data are expressed as mean ± standard deviation

Abbreviations: WHOQOL-BREF the World Health Organization Quality of Life Brief Scale

Fig. 2

Total score of WHOQOL-BREF by CHADS2 score stratified by depressive symptoms. The total score of WHOQOL-BREF decreases siginificantly with increasing CHADS 2 score in both subgroups (Ps < 0.001). Error bars represent standard deviation. PHQ-9: Patient Health Questionnaire-9; WHOQOL-BREF: World Health Organization Quality of Life Brief Scale

Association between CHADS2 score and depressive symptoms

The associations between each item in CHADS2, CHADS2 score and depressive symptoms were examined by univariate and multivariate logistic regression analyses (Table 2). Heart failure and stroke were independently associated with depressive symptoms after adjusting for other items in CHADS2 and clinical covariates, including gender, BMI, TC, TG, LDL-C, HDL-C, serum uric acid, eGFR, smoking, drinking, education, income, physical activity, and sleep time (Ps < 0.001). However, the associations between hypertension, age ≥ 75 years, diabetes mellitus and depressive symptoms were significant only in univariate model (Ps ≤ 0.001) but not in multivariate model (Ps > 0.05). Subjects with CHADS2 score ≥ 3 had significantly higher independent risk of depressive symptoms than those with CHADS2 score = 0 after adjusting for clinical covariates (all Ps < 0.05).

Association between CHADS2 score and QoL

To explore the associations between CHADS2 score and QoL, a multivariate linear regression analysis was conducted for each item in CHADS2, and optimal scale regression analysis was used for CHADS2 score (as ordinal variate) (Table 4). Generally speaking, items in CHADS2 were negatively associated with scores of WHOQOL-BREF. Congestive heart failure, age ≥ 75 years, diabetes mellitus, and stroke were all independently negatively associated with the total score of WHOQOL-BREF after adjusting for gender, BMI, TC, TG, LDL-C, HDL-C, serum uric acid, eGFR, smoking, drinking, education, income, physical activity, sleep time, and other items in CHADS2 (all Ps < 0.05). Optimal scale regression analysis showed CHADS2 score was independently negatively associated with all scores of WHOQOL-BREF (all Ps < 0.001).
Table 4

Multivariate linear and optimal scale regression analyses for associations between CHADS2 score and WHOQOL-BREF

 

Overall quality of life

General health

Domains

Total score

Physical health

Psychological

Social relationships

Environment

Congestive heart failurea

       

 β

−0.106

−0.482

−1.771

−1.092

−0.528

−0.482

−4.458

P value

0.113

<0.001

<0.001

<0.001

0.008

0.016

<0.001

Hypertensiona

       

 β

0.006

−0.073

−0.154

0.061

−0.097

0.075

−0.169

P value

0.690

<0.001

<0.001

0.193

0.018

0.071

0.284

Age ≥ 75 yearsa

       

 β

0.115

0.230

−0.492

−0.070

−0.581

−0.093

−0.877

P value

0.003

<0.001

<0.001

0.596

<0.001

0.426

0.047

Diabetes mellitusa

       

 β

−0.039

−0.190

−0.368

−0.307

−0.160

−0.132

−1.198

P value

0.191

<0.001

<0.001

0.003

0.072

0.145

<0.001

Strokea

       

 β

−0.091

−0.377

−1.192

−0.809

−0.469

−0.384

−3.298

P value

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

CHADS2 scoreb

       

 β

−0.045

−0.170

−0.180

−0.098

−0.098

−0.058

−0.130

P value

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

Abbreviations: CI confidence interval, WHOQOL-BREF the World Health Organization Quality of Life Brief Scale

aby multivariate linear regression analysis adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid cholesterol, serum uric acid, estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, sleep time, and other items in CHADS2

bby optimal scale regression analysis adjusted for all factors in model α except for items in CHADS2

Discussion

The results of this study demonstrated that the CHADS2 score is significantly associated with depressive symptoms and QoL in a large general population. The tools of WHOQOL-BREF and PHQ-9 were chosen to evaluate QoL and depressive symptoms, respectively. With increasing CHADS2 score, the prevalence of depressive symptoms (PHQ-9 score ≥ 10) increases, while the total score and every domain of WHOQOL-BREF decreases. The independent associations were still observed after adjusting for confounding risk factors.

Previous studies demonstrated that the components of CHADS2 score were associated with depression and poor QoL. Depression in patients with heart failure was 4–5 times that of the general population [28], and QoL was greatly impaired among patients with heart failure [29]. A systemic review showed that the general prevalence of depression was as high as 26.8% among hypertensive patients [14], and hypertension also impaired QoL [30]. Diabetes had a marked increase in depression prevalence, however, a reduction in QoL [31]. Moreover, depression was a common and serious complication after stroke, affecting nearly 30% of patients at different stages [32]. The possible reasons for lower QoL and depressive symptoms among these patients included having chronic diseases, being aware of them, and comprehensive treatment [33]. In this current study, only heart failure and stroke were independently associated with depressive symptoms, while old age, hypertension, and diabetes mellitus had no significant independent relation. All items in CHADS2 except for hypertension were associated with impaired QoL. These results were somewhat consistent with previous ones. Relatively low education level, awareness, and treatment of chronic diseases in rural China may partially contribute to the differences [34, 35].

The scheme of the CHADS2 score has been used widely, and a CHADS2 score ≥ 2 is considered as the risk factor for stroke in AF patients. Recent study showed that patients with a CHADS2 score ≥ 2 was also significantly associated with peripheral arterial occlusive disease among non-AF population [12]. The present study in the general population demonstrated that subjects with CHADS2 score ≥ 3 had significantly higher risk of depressive symptoms than those with CHADS2 score = 0 after adjusting for clinical covariates. Furthermore, CHADS2 score was negatively associated with all scores of WHOQOL-BREF. Previous study showed that depression was accompanied by poor QoL with low scores of WHOQOL-BREF [36]. This study found that CHADS2 score was negatively associated with the total score of WHOQOL-BREF whether or not the subjects had depressive symptoms. This is the first study to reveal the associations of CHADS2 score with depressive symptoms and impaired QoL.

This study has several limitations. First, the current study is cross-sectional and it was not clear whether the CHADS2 score would predict the incidence of depressive symptoms. Second, congestive heart failure and stroke were diagnosed based on a previous history of physician-diagnosis since a large sample was involved. This approach may give rise to an unintentional bias though it had been utilized in previous studies [23, 37]. Third, the current study was part of NCRCHS, and subjects with severe mental disorders who couldn’t complete the survey were excluded. This may have a potential bias on the results. Fourth, the relatively small sample in some subgroups may have reduced the statistical power, and further studies with larger sample were needed to confirm the results.

Conclusions

This is the first study to demonstrate that the CHADS2 score is significantly associated with depressive symptoms and impaired QoL in the general Chinese population. Much attention should also be paid to depressive symptoms and QoL among patients with high CHADS2 score.

Abbreviations

AF: 

Atrial fibrillation

CI: 

Confidence interval

CVD: 

Cardiovascular diseases

DBP: 

Diastolic blood pressure

FBG: 

Fasting blood glucose

GFR: 

Glomerular filtration rate

HDL-C: 

High density lipid cholesterol

LDL-C: 

Low density lipid cholesterol

OR: 

Odds ratio

PHQ-9: 

Patient Health Questionnaire-9

QoL: 

Quality of life

SBP: 

Systolic blood pressure

TC: 

Total cholesterol

TG: 

Triglycerides

WHO: 

World Health Organization

WHOQOL-BREF: 

World Health Organization Quality of Life Brief Scale

Declarations

Acknowledgements

This study was founded by the National Science and Technology Support Program of China (No. 2012BAJ18B08-7) and Liaoning Research Center for Translational Medicine of Cardiovascular Disease (No. 2014225017).

Availability of data and materials

The datasets generated during and analysed during the current study are not publicly available, and we do not wish to share our data. But they are available from the corresponding author on reasonable request.

Authors’ contributions

GZS participated in the investigation, collected the data, performed the statistical analysis and prepared the first draft of the manuscript. NY participated in the questionnaire and reviewed the manuscript. NJZ performed the weight and height measurements and coordinated the questionnaire. YL participated in the blood pressure measurements and carried out the blood samples collection. SC and YC coordinated the data collection. ZL participated in the study design and supervised the data collection during investigation. YXS conceived the study design, reviewed the manuscript and served as the guarantor for the paper. All authors approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of China Medical University (Shenyang, China). All procedures were performed in accordance with the ethical standards.

Written consent was obtained from all participants. In the case of an illiterate participant, written informed consent was obtained from the appropriate legal proxy.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiovascular Medicine, The First Hospital of China Medical University

References

  1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the international consortium of psychiatric epidemiology (ICPE) surveys. Int J Methods Psychiatr Res. 2003;12:3–21.View ArticlePubMedGoogle Scholar
  2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–7.Google Scholar
  3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet. 1997;349:1498–504.View ArticlePubMedGoogle Scholar
  4. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153–60.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA. 2006;295:2874–81.View ArticlePubMedPubMed CentralGoogle Scholar
  6. WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–9.
  7. Cepeda-Valery B, Cheong AP, Lee A, Yan BP. Measuring health related quality of life in coronary heart disease: the importance of feeling well. Int J Cardiol. 2011;149:4–9.View ArticlePubMedGoogle Scholar
  8. Ko HY, Lee JK, Shin JY, Jo E. Health-related quality of life and cardiovascular disease risk in Korean adults. Korean J Fam Med. 2015;36:349–56.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287–92.View ArticlePubMedGoogle Scholar
  10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–70.View ArticlePubMedGoogle Scholar
  11. Poçi D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidahl K. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141:1431–40.View ArticlePubMedGoogle Scholar
  12. Hsu PC, Lin TH, Lee WH, Chu CY, Chiu CA, Lee HH, et al. Association between the CHADS2 score and an ankle-brachial index of < 0.9 in patients without atrial fibrillation. J Atheroscler Thromb. 2014;21:322–8.View ArticlePubMedGoogle Scholar
  13. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.View ArticlePubMedGoogle Scholar
  14. Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e1317.View ArticleGoogle Scholar
  15. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.View ArticlePubMedGoogle Scholar
  16. Fei K, Benn EK, Negron R, Arniella G, Tuhrim S, Horowitz CR. Prevalence of depression among stroke survivors: racial-ethnic differences. Stroke. 2016;47:512–5.View ArticlePubMedGoogle Scholar
  17. Zhou X, Bi B, Zheng L, Li Z, Yang H, Song H, et al. The prevalence and risk factors for depression symptoms in a rural Chinese sample population. Plos One. 2014;9:e99692.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the patient health questionnaire (PHQ-9). J Affect Disord. 2004;81:61–6.View ArticlePubMedGoogle Scholar
  19. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Manea L, Gilbody S, Mcmillan D. Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012;184:E191–6.View ArticlePubMedPubMed CentralGoogle Scholar
  21. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:551–8.View ArticleGoogle Scholar
  22. Skevington SM, Lotfy M, O’Connell KA, WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.View ArticlePubMedGoogle Scholar
  23. Chao TF, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL, et al. CHADS2 and CHA2DS2-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol. 2011;58:2380–5.View ArticlePubMedGoogle Scholar
  24. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.View ArticlePubMedGoogle Scholar
  25. World Health Organization and International Diabetes Fedaration. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO; 2006. p. 1–3.Google Scholar
  26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Hu G, Tuomilehto J, Silventoinen K, Barengo N, Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged finnish men and women. Eur Heart J. 2004;25:2212–9.View ArticlePubMedGoogle Scholar
  28. Khan S, Khan A, Ghaffar R, Awan ZA. Frequency of depression in patients with chronic heart failure. J Ayub Med Coll Abbottabad. 2012;24:26–9.PubMedGoogle Scholar
  29. Berry C, Mcmurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999;16:247–71.View ArticlePubMedGoogle Scholar
  30. Carvalho MV, Siqueira LB, Sousa AL, Jardim PC. The influence of hypertension on quality of life. Arq Bras Cardiol. 2013;100:164–74.View ArticlePubMedGoogle Scholar
  31. Mishra SR, Sharma A, Bhandari PM, Bhochhibhoya S, Thapa K. Depression and health-related quality of life among patients with type 2 diabetes mellitus: a cross-sectional study in Nepal. Plos One. 2015;10:e0141385.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat. 2008;4:145–54.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Hayes DK, Denny CH, Keenan NL, Croft JB, Greenlund KJ. Health-related quality of life and hypertension status, awareness, treatment, and control: National Health and Nutrition Examination Survey, 2001–2004. J Hypertens. 2008;26:641–7.View ArticlePubMedGoogle Scholar
  34. Bundy JD, He J. Hypertension and related cardiovascular disease burden in China. Ann Glob Health. 2016;82:227–33.View ArticlePubMedGoogle Scholar
  35. Liu X, Li Y, Li L, Zhang L, Ren Y, Zhou H, et al. Prevalence, awareness, treatment, control of type 2 diabetes mellitus and risk factors in Chinese rural population: the RuralDiab study. Sci Rep. 2016;6:31426.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Chang YC, Yao G, Hu SC, Wang JD. Depression affects the scores of all facets of the WHOQOL-BREF and may mediate the effects of physical disability among community-dwelling older adults. Plos One. 2015;10:e0128356.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301–6.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement